{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:44:43Z","timestamp":1773297883507,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012540","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T00:00:00Z","timestamp":1526083200000}}],"reference-count":112,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012540.pub2","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T09:55:46Z","timestamp":1526291746000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease"],"prefix":"10.1002","volume":"2018","author":[{"given":"Ray K","family":"Boyapati","sequence":"first","affiliation":[{"name":"Monash Health; Department of Gastroenterology; Clayton Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Torres","sequence":"additional","affiliation":[{"name":"Icahn Medical School of Medicine at Mount Sinai; Department of Medicine, Division of Gastroenterology; New York Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Palmela","sequence":"additional","affiliation":[{"name":"Hospital Beatriz \u00c2ngelo; Division of Gastroenterology, Surgical Department; Loures Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orli M","family":"Silverberg","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Health Sciences; London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonam D","family":"Upadhyaya","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Health Sciences; London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Icahn Medical School of Medicine at Mount Sinai; Department of Medicine, Division of Gastroenterology; New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,12]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD012540.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine","volume":"128","author":"L\u00e9mann","year":"2005","journal-title":"Gastroenterology"},{"issue":"8097","key":"10.1002\/14651858.CD012540.pub2-BIB0002|cit2","first-page":"955-7","article-title":"Double blind withdrawal trial of azathioprine as maintenance treatment for Crohn\u2019s disease","volume":"2","author":"O\u2019Donoghue","year":"1978","journal-title":"Lancet"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0016-5085(16)30584-4","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: A prospective study","volume":"150","author":"Tedesco","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0004|cit4","first-page":"S7","article-title":"Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: A prospective study","volume":"10","author":"Tedesco","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD012540.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: A randomized trial","volume":"134","author":"Assche","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012540.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2004.01944.x","article-title":"Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn\u2019s disease: Increased relapse rate the following year","volume":"19","author":"Vilien","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012540.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","article-title":"Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn\u2019s disease","volume":"60","author":"Wenzl","year":"2015","journal-title":"Digestive Diseases and Science"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clinre.2015.05.019","article-title":"Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission","volume":"40","author":"Amiot","year":"2016","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jgh.13348","article-title":"Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion","volume":"31","author":"Begun","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology (Australia)"},{"issue":"5","key":"10.1002\/14651858.CD012540.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/apt.13066","article-title":"Letter: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease","volume":"41","author":"Benitez","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0012|cit12","first-page":"e137","article-title":"IBD recurrence after stopping anti-TNF-alpha therapy: A prospective randomized controlled study comparing mesalamine and azathioprine-preliminary results","volume":"47","author":"Bodini","year":"2015","journal-title":"Digestive and Liver Disease"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0013|cit13","first-page":"S61","article-title":"Deep remission in Crohn's disease does not prevent disease relapse after withdrawal of anti-TNF alpha therapy","volume":"148","author":"Bortlik","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ecco-jcc\/jju027.007","article-title":"Deep remission in Crohn's disease does not prevent disease relapse after withdrawal of anti-TNFa therapy","volume":"9","author":"Bortlik","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD012540.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/00365521.2015.1079924","article-title":"Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: A prospective observation","volume":"51","author":"Bortlik","year":"2016","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S814","DOI":"10.1016\/S0016-5085(16)32753-6","article-title":"Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy","volume":"1)","author":"Bots","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0017|cit17","first-page":"S397","article-title":"Relapse risk and predictors for relapse in a real-life cohort of inflammatory bowel disease patients after discontinuation of anti-tumour necrosis factor therapy","volume":"10","author":"Bots","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"8996","key":"10.1002\/14651858.CD012540.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(96)90402-X","article-title":"Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine","volume":"347","author":"Bouhnik","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD012540.pub2-BIB0019|cit19","first-page":"1456","article-title":"Outcome of elective withdrawal of anti-tumour necrosis factor-alpha therapy in patients with Crohn's disease in established remission","volume":"11","author":"Brooks","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD012540.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/apt.13368","article-title":"Letter: Infliximab de-escalation based on trough levels in patients with inflammatory bowel disease","volume":"42","author":"Chaparro","year":"2015","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD012540.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.dld.2014.04.012","article-title":"Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study","volume":"46","author":"Chauvin","year":"2014","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0022|cit22","first-page":"11","article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease: Outcome and risk factors","volume":"16","author":"Chen","year":"2015","journal-title":"Journal of Digestive Diseases"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0023|cit23","first-page":"154","article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease: Outcome and risk factors","volume":"30","author":"Chen","year":"2015","journal-title":"Journal of Gastroenterology and Hepatology (Australia)"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0024|cit24","first-page":"S355","article-title":"Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: Economic and clinical implications","volume":"10","author":"Cortes","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0025|cit25","first-page":"S300","article-title":"Long-term outcome of treatment with infliximab in paediatric Crohn's disease: A population-based study","volume":"138","author":"Crombe","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0026|cit26","first-page":"E114","article-title":"Long-term outcome of treatment with infliximab (IFX) in pediatric Crohn's disease (CD): A population-based study","volume":"50","author":"Crombe","year":"2010","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"10","key":"10.1002\/14651858.CD012540.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ibd.21615","article-title":"Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study","volume":"17","author":"Crombe","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"10","key":"10.1002\/14651858.CD012540.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"e110797","DOI":"10.1371\/journal.pone.0110797","article-title":"Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy","volume":"9","author":"Dai","year":"2014","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1002\/14651858.CD012540.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","article-title":"Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety","volume":"65","author":"Lima","year":"2016","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1873-9946(12)60294-3","article-title":"Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients: A sub-analysis of the STORI study","volume":"6","author":"Suray","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0016-5085(12)60560-5","article-title":"Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A sub-analysis of the STORI study","volume":"142","author":"Suray","year":"2012","journal-title":"Gastroenterology"},{"issue":"11-12","key":"10.1002\/14651858.CD012540.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-2036.2005.02670.x","article-title":"Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: How long should patients be treated?","volume":"22","author":"Domenech","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0033|cit33","first-page":"S","article-title":"Deep remission in Crohn\u2019s disease does not prevent disease relapse after withdrawal of anti-TNFa therapy","volume":"148","author":"Duricov\u00e1","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/S1873-9946(13)60424-9","article-title":"Predictors of relapse after discontinuing anti-TNF therapy in Crohn's disease patients on deep remission","volume":"7","author":"Echarri","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"issue":"11","key":"10.1002\/14651858.CD012540.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.3748\/wjg.v20.i11.2995","article-title":"Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy","volume":"20","author":"Farkas","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0036|cit36","first-page":"A17","article-title":"Efficacy of vedolizumab with and without continued immunosuppressant use in GEMINI 1 and GEMINI 2","volume":"1","author":"Feagan","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S791","DOI":"10.14309\/00000434-201510001-01862","article-title":"Efficacy of vedolizumab maintenance therapy with and without continued immunosuppressant use in GEMINI 1 and GEMINI 2","volume":"110","author":"Feagan","year":"2015","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0038|cit38","first-page":"S","article-title":"Risk factors for rescue therapy in Crohn\u2019s patients on combination therapy after discontinuation of the immunomodulator","volume":"146","author":"Fischer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0039|cit39","first-page":"A237","article-title":"Ileal Crohn's disease: Magnetic resonance enterography as a predictor of relapse after antiTNF discontinuation","volume":"1","author":"Gallego","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"10","key":"10.1002\/14651858.CD012540.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","article-title":"Concomitant use of immunomodulators affects the durability of infliximab therapy in children With Crohn's disease","volume":"13","author":"Grossi","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1093\/ecco-jcc\/jju027.387","article-title":"Maintenance of remission after prolonged therapy with Infliximab: A \"real-life\" experience from a single Italian centre in patients affected by Crohn's Disease and Ulcerative Colitis","volume":"9","author":"Grossi","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0042|cit42","first-page":"S252","article-title":"Proposal for an anti-tumour necrosis factor-exit strategy based on trough serum level","volume":"10","author":"Helwig","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0043|cit43","first-page":"85","article-title":"Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease","volume":"55","author":"Helwig","year":"2017","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0044|cit44","first-page":"S337","article-title":"Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: A prospective single-centre open label study","volume":"10","author":"Hlavaty","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1093\/ecco-jcc\/jjw019.578","article-title":"Risk of relapse after azathioprine discontinuation in inflammatory bowel disease patients in maintained remission","volume":"10","author":"Iborra","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.1016\/S0016-5085(16)31534-7","article-title":"Risk of relapse after azathioprine (AZA) discontinuation in inflammatory bowel disease (IBD) patients in maintained remission","volume":"150","author":"Iborra","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00054725-201112002-00156","article-title":"Long term outcome of top-down therapy in Crohn\u2019s disease: a single center experience","volume":"17","author":"Iimuro","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0048|cit48","first-page":"S350","article-title":"Factors associated with relapse after infliximab cessation in pediatric Crohn's disease patients treated with combined immunosuppression","volume":"63","author":"Kang","year":"2016","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"8","key":"10.1002\/14651858.CD012540.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/apt.13547","article-title":"Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: An observational study, plus systematic review and meta-analysis","volume":"43","author":"Kennedy","year":"2016","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012540.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","volume":"60","author":"Kierkus","year":"2015","journal-title":"Journal of Pediatric Gastroenterology & Nutrition"},{"issue":"11","key":"10.1002\/14651858.CD012540.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1111\/j.1572-0241.1999.01532.x","article-title":"Optimum duration of treatment with 6-mercaptopurine for Crohn's disease","volume":"94","author":"Kim","year":"1999","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012540.pub2-BIB0053|cit53","first-page":"1021","article-title":"Outcome after discontinuation of TNF alpha-blocking therapy in patients with inflammatory bowel disease in deep remission","volume":"20","author":"Molander","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0054|cit54","first-page":"33","article-title":"Does fecal calprotectin predict short-term relapse after stopping TNFalpha-blocking agents in inflammatory bowel disease patients in deep remission?","volume":"9","author":"Molander","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0055|cit55","first-page":"S47","article-title":"Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha -blocking agents","volume":"10","author":"Molander","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD012540.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/apt.12160","article-title":"Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy","volume":"37","author":"Molnar","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0057|cit57","first-page":"e100","article-title":"Maintenance of clinical remission in Crohn's disease patients after discontinuation of long term treatment with infliximab: Results of a single centre cohort","volume":"47","author":"Monterubbianesi","year":"2015","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S1590-8658(16)30219-5","article-title":"Maintenance of clinical remission in IBD patients after discontinuation of anti-TNF agents, an Italian experience","volume":"48","author":"Monterubbianesi","year":"2016","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0059|cit59","first-page":"S386","article-title":"Maintenance of clinical remission in inflammatory bowel disease patients after discontinuation of anti-TNF agents, an Italian experience","volume":"10","author":"Monterubbianesi","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0060|cit60","first-page":"E108","article-title":"Long term efficacy of infliximab in inflammatory bowel disease at a single tertiary center","volume":"50","author":"Nuti","year":"2010","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S1590-8658(10)60555-5","article-title":"Long term efficacy of infliximab in inflammatory bowel disease at a single tertiary center","volume":"42","author":"Nuti","year":"2010","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0062|cit62","first-page":"A617","article-title":"Infliximab de-escalation based on trough levels in inflammatory bowel disease patients: A proof-of concept study","volume":"1","author":"Paul","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0063|cit63","first-page":"A434","article-title":"Predictors of disease relapse of patients with Crohn's disease in deep remission: Who and when can withdraw thiopurine maintenance therapy?","volume":"1","author":"Qiu","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/ecco-jcc\/jju027.092","article-title":"Predictors of disease relapse of patients with Crohn's disease in deep remission: Who and when can withdraw thiopurine maintenance therapy?","volume":"9","author":"Qiu","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"issue":"3","key":"10.1002\/14651858.CD012540.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/00365521.2012.758773","article-title":"Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease","volume":"48","author":"Rismo","year":"2013","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012540.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0067|cit67","first-page":"S70","article-title":"Anti-TNF therapy and pregnancy in inflammatory bowel disease: A prospective cohort study from the GETAID","volume":"5 (1)","author":"Seirafi","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/S0016-5085(11)60708-7","article-title":"Anti-TNF therapy and pregnancy in inflammatory bowel disease: A prospective cohort study from the GETAID","volume":"140","author":"Seirafi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"A437","DOI":"10.1136\/gutjnl-2015-309861.959","article-title":"Prospective anti-TNF withdrawal in quiescent Crohn's disease-12 month clinical outcomes","volume":"64","author":"Squires","year":"2015","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0070|cit70","first-page":"A32","article-title":"Optimization of thiopurine therapy improves remission rates after cessation of anti-TNFa in Crohn's disease","volume":"1","author":"Thomsen","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2008.08.028","article-title":"Azathioprine withdrawal in patients With Crohn's disease maintained on prolonged remission: A high risk of relapse","volume":"7","author":"Treton","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012540.pub2-BIB0072|cit72","first-page":"S685","article-title":"Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: Long term follow-up of a single center cohort","volume":"138","author":"Waugh","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD012540.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1365-2036.2010.04446.x","article-title":"Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort","volume":"32","author":"Waugh","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012540.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MPG.0b013e31815604cd","article-title":"12-month follow-up after successful infliximab therapy in pediatric Crohn's disease","volume":"46","author":"Wynands","year":"2008","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD012540.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clinical Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0076|cit76","unstructured":"NCT01817426 Discontinuation of infliximab therapy in patients with CD during sustained complete remission (STOP IT) clinicaltrials.gov\/ct2\/show\/NCT01817426"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0077|cit77","unstructured":"NCT02177071 A prospective randomized controlled trial comparing infliximab-antimetabolites combination therapy to antimetabolites monotherapy and infliximab monotherapy in Crohn's disease patients in sustained steroid-free remission on combination therapy (SPARE) clinicaltrials.gov\/ct2\/show\/NCT02177071"},{"issue":"23","key":"10.1002\/14651858.CD012540.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Andersen","year":"2014","journal-title":"JAMA"},{"issue":"9701","key":"10.1002\/14651858.CD012540.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012540.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/j.1572-0241.2006.00603.x","article-title":"The epidemiology of inflammatory bowel disease in Canada: a population-based study","volume":"101","author":"Bernstein","year":"2006","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012540.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crohns.2013.01.014","article-title":"Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis","volume":"7","author":"Billioud","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD012540.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"Bourrier","year":"2016","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD012540.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2036.2012.05002.x","article-title":"Review article: the natural history of postoperative Crohn's disease recurrence","volume":"35","author":"Buisson","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD012540.pub2-BIB0084|cit84","first-page":"486","article-title":"Understanding combination therapy with biologics and immunosuppressives for the treatment of Crohn's disease","volume":"6","author":"Colombel","year":"2010","journal-title":"Gastroenterology and Hepatology"},{"issue":"15","key":"10.1002\/14651858.CD012540.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012540.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrgastro.2009.222","article-title":"Top-down therapy for IBD: rationale and requisite evidence","volume":"7","author":"D'Haens","year":"2010","journal-title":"Nature Reviews Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal (\u2018exit strategies\u2019) in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7109","key":"10.1002\/14651858.CD012540.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD012540.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s10620-011-1671-5","article-title":"Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis","volume":"56","author":"French","year":"2011","journal-title":"Digestive Diseases and Sciences"},{"issue":"10","key":"10.1002\/14651858.CD012540.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.mib.0000231572.88806.b9","article-title":"High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study","volume":"12","author":"Gearry","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012540.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fimmu.2015.00489","article-title":"Intestinal microbiota and the innate immune system - a crosstalk in Crohn's disease pathogenesis","volume":"6","author":"Haag","year":"2015","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1002\/14651858.CD012540.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations of inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7414","key":"10.1002\/14651858.CD012540.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0096|cit96","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0097|cit97","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0098|cit98","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD012540.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and non melanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012540.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/apt.12838","article-title":"Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases","volume":"40","author":"Pariente","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012540.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0103|cit103","first-page":"1693-1701","article-title":"Surgery in a population-based cohort of Crohn\u2019s disease from Olmsted County, Minnesota (1970 - 2004)","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"American Joural of Gastroenterology"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0104|cit104","article-title":"Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors(s)","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration","author":"Sch\u00fcnemann","year":"2011"},{"issue":"8","key":"10.1002\/14651858.CD012540.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012540.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"362-3","DOI":"10.1002\/ibd.20981","article-title":"Current smoking, not duration of remission, delays Crohn\u2019s disease relapse following azathioprine withdrawal","volume":"16","author":"Sokol","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012540.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/imj.12363","article-title":"Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?","volume":"44","author":"Subramaniam","year":"2014","journal-title":"Internal Medicine Journal"},{"issue":"12","key":"10.1002\/14651858.CD012540.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00042737-199812000-00005","article-title":"Patients consulting with Crohn's disease in primary care in England and Wales","volume":"10","author":"Thompson","year":"1998","journal-title":"European Journal of Gastroenterology Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012540.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012540.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"Valk","year":"2014","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012540.pub2-BIB0111|cit111","unstructured":"Wells GA Shea B O'Connell D Peterson J Welch V Losos M The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. (accessed 30 January 2017)"},{"issue":"9","key":"10.1002\/14651858.CD012540.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/ibd.21209","article-title":"High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study","volume":"16","author":"Wilson","year":"2010","journal-title":"Inflammatory Bowel Diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012540.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T02:48:12Z","timestamp":1673318892000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012540.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,12]]},"references-count":112,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012540.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,12]]}}}